We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-13.57%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$241M
AUM Growth
-$120M
Cap. Flow
-$12M
Cap. Flow %
-5%
Top 10 Hldgs %
81.75%
Holding
117
New
44
Increased
16
Reduced
22
Closed
31

Top Buys

Rank Stock Value
1
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$3.34M
2
ENLV icon
Enlivex Ltd
ENLV
+$3.28M
3
BXRX
Baudax Bio, Inc. Common Stock
BXRX
+$2.52M
4
NOVN
Novan, Inc. Common Stock
NOVN
+$2.52M
5
OTLK icon
Outlook Therapeutics
OTLK
+$2.36M

Top Sells

Rank Stock Value
1
TRAW icon
Traws Pharma
TRAW
+$3.35M
2
GLD icon
SPDR Gold Trust
GLD
+$2.92M
3
HIND
Vyome Holdings
HIND
+$1.31M
4
GNPX icon
Genprex
GNPX
+$1.03M
5
PAVMZ
PAVmed Inc. Series Z Warrant
PAVMZ
+$891K

Sector Composition

Rank Sector Weight
1 Healthcare 7.26%
2 Technology 0.29%
3 Financials 0.15%
4 Consumer Discretionary 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BXRX
26
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$927K 0.39%
+267
New +$2.52M
TTPH
27
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$854K 0.35%
+667,000
New +$1.36M
CTXR icon
28
Citius Pharmaceuticals
CTXR
$13.7M
$813K 0.34%
+54,171
New +$1.14M
PLUR icon
29
PUT
Pluri
PLUR
$18.1M
$768K 0.32%
262
+37
+16% +$1.11K
GNCA
30
DELISTED
Genocea Biosciences, Inc.
GNCA
$757K 0.31%
440,274
-98,085
-18% -$198K
PLUR icon
31
Pluri
PLUR
$18.1M
$705K 0.29%
24,006
+16,951
+240% +$508K
BPTH
32
DELISTED
Bio-Path Holdings Inc
BPTH
$694K 0.29%
7,715
+1,548
+25% +$184K
IWM icon
33
iShares Russell 2000 ETF
IWM
$80.4B
$675K 0.28%
+5,900
New +$880K
CVM icon
34
CEL-SCI Corp
CVM
$21M
$635K 0.26%
+1,835
New +$671K
ASXC
35
DELISTED
Asensus Surgical, Inc.
ASXC
$619K 0.26%
+1,760,262
New +$1.84M
AUPH icon
36
Aurinia Pharmaceuticals
AUPH
$1.92B
$617K 0.26%
+42,500
New +$750K
AMRN
37
Amarin Corp
AMRN
$293M
$600K 0.25%
7,500
+6,159
+459% +$2.05M
ORMP icon
38
PUT
Oramed Pharmaceuticals
ORMP
$171M
$550K 0.23%
1,809
+247
+16% +$1.08K
SRNE
39
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$529K 0.22%
287,386
+260,208
+957% +$749K
PHIO icon
40
Phio Pharmaceuticals
PHIO
$11.7M
$452K 0.19%
+2,363
New +$1.46M
AUPH icon
41
CALL
Aurinia Pharmaceuticals
AUPH
$1.92B
$448K 0.19%
309
+18
+6% +$318
AVEO
42
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$406K 0.17%
+112,155
New +$557K
TRIL
43
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$404K 0.17%
+1,000
New +$3.78K
PTE
44
DELISTED
PolarityTE, Inc. Common Stock
PTE
$377K 0.16%
+13,974
New +$757K
PHAS
45
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$356K 0.15%
107,577
+13,226
+14% +$60.5K
SRNE
46
PUT
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$289K 0.12%
1,569
-1,902
-55% -$5.48K
COCP icon
47
Cocrystal Pharma
COCP
$12.9M
$278K 0.12%
+32,684
New +$308K
ASTC icon
48
Astrotech Corp
ASTC
$12.9M
$259K 0.11%
+3,322
New +$192K
SEEL
49
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$249K 0.1%
+132
New +$491K
HSDT icon
50
Solana Company
HSDT
$98.7M
$246K 0.1%
+1
New +$1.08M
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2020 Portfolio in Review

As of Q1 2020, Sabby Management held 117 positions worth $241M, down 33% from $361M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Sabby Management withdrew a net $12M in Q1 2020, closing 31 positions and reducing 22 holdings. Its most notable exit was Traws Pharma, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, up from 5.4% a quarter earlier, followed by Technology and Financials.

Against the trend, Sabby Management opened a new position in State Street Health Care Select Sector SPDR ETF worth $3.05M.

  • Sabby Management's largest Q1 2020 buy was State Street Health Care Select Sector SPDR ETF: 34,410 shares worth $3.05M.
  • Sabby Management added most to Outlook Therapeutics in Q1 2020, an estimated $2.36M increase.
  • Sabby Management's biggest Q1 2020 reduction was SPDR Gold Trust, cutting an estimated $2.92M.
  • Sabby Management fully exited Traws Pharma in Q1 2020, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 82% of its $241M portfolio in Q1 2020.
  • Sabby Management opened 44 new positions and closed 31 in Q1 2020.
  • Sabby Management's portfolio value fell 33% quarter-over-quarter to $241M.

Based on Sabby Management's 13F filing for Q1 2020, filed 15 May 2020.